KBC Group NV Sells 12,336 Shares of Repligen Co. (NASDAQ:RGEN)

KBC Group NV decreased its holdings in Repligen Co. (NASDAQ:RGENFree Report) by 60.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,167 shares of the biotechnology company’s stock after selling 12,336 shares during the period. KBC Group NV’s holdings in Repligen were worth $1,469,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. lifted its stake in Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares in the last quarter. Principal Securities Inc. bought a new position in Repligen during the fourth quarter valued at approximately $48,000. Headlands Technologies LLC purchased a new position in Repligen during the 3rd quarter valued at approximately $75,000. Signaturefd LLC grew its holdings in Repligen by 48.4% during the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 136 shares in the last quarter. Finally, Picton Mahoney Asset Management bought a new stake in Repligen in the 4th quarter worth approximately $90,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $145.78 on Friday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The stock has a market cap of $8.15 billion, a PE ratio of 583.14, a P/E/G ratio of 4.96 and a beta of 1.04. The company has a 50-day moving average price of $164.74 and a 200 day moving average price of $177.29.

Repligen (NASDAQ:RGENGet Free Report) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter last year, the firm earned $0.64 EPS. The firm’s quarterly revenue was down 17.1% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of recent research reports. KeyCorp raised their target price on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $197.75.

Check Out Our Latest Analysis on RGEN

Repligen Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.